Ro vs Henry Meds: Which Telehealth GLP-1 Model Fits Your Needs

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ro and Henry Meds have emerged as prominent telehealth intermediaries for GLP-1 prescription access, collectively serving hundreds of thousands of patients seeking weight management and metabolic support. Both platforms leverage remote consultations and pharmacy networks, but their operational models, prescriber credentials, medication sourcing, and pricing differ significantly—factors that merit careful evaluation for anyone exploring GLP-1 therapy.

The choice between Ro, Henry Meds, traditional in-person providers, and precision-compounded alternatives hinges on clinical oversight quality, medication bioavailability, genetic responsiveness context, and total cost of care. This article dissects what each platform offers and introduces how personalized compounded GLP-1 protocols, informed by genetic predisposition testing, represent a clinically distinct pathway.

What Ro and Henry Meds Actually Do

Ro operates as a vertically integrated telehealth service, connecting patients with licensed prescribers—typically nurse practitioners or physician assistants—via app-based consultations. Ro sources branded GLP-1 medications (Wegovy, Ozempic) through contracted pharmacies and manages ongoing monitoring, dose adjustments, and refills within its proprietary ecosystem.

Henry Meds functions as a telehealth marketplace, linking patients to independent practitioners (MDs, DOs, NPs) who evaluate candidacy and issue prescriptions fulfilled through third-party pharmacies. Henry Meds does not dispense medications directly; it acts as a clinical coordination and prescription-routing platform, offering more provider flexibility than Ro's employed-clinician model.

Operational Model, Prescriber Types, and Clinical Oversight Framework

The prescriber credential and oversight structure differs between platforms. Ro employs in-house clinicians who follow standardized protocols, ensuring consistency but potentially less individualized evaluation. Henry Meds recruits independent practitioners with variable credentials and specialties, permitting more tailored assessments but introducing greater variability in clinical depth and follow-up quality.

Factor	Ro Model	Henry Meds Model	Compounded GLP-1 (PlexusDx Partner)
Prescriber Employment	In-house, salaried clinicians (NPs, PAs)	Independent MDs, DOs, NPs via marketplace	Licensed MDs/DOs with personalized review
Medication Source	Branded (Wegovy, Ozempic) via contracted pharmacies	Branded via third-party pharmacies	503A compounded semaglutide, tirzepatide from licensed compounding pharmacies
Dose Titration Flexibility	Fixed-schedule, protocol-driven	Provider-directed, case-by-case	Customized microdose to standard dosing; genetic pathway insight available
Typical Monthly Cost Range	$199–$399 (branded medication + telehealth fee)	$199–$349 (branded medication + consultation fee)	$129-$369/mo (compounded formulation, no inherent markup)

Medication Sourcing and Bioavailability Distinctions

Both Ro and Henry Meds dispense FDA-approved branded GLP-1 medications, manufactured under strict pharma regulations. However, branded products often face supply constraints and premium pricing. Compounded semaglutide and tirzepatide, while not FDA-approved as finished drugs, are manufactured by licensed 503A compounding pharmacies under USP <797> standards and may offer cost predictability and microdose options for patients seeking granular titration or those experiencing branded-product shortages.

The choice between branded and compounded hinges on clinical objectives, risk tolerance, and access priorities. Branded medications have extensive post-market surveillance and uniform potency assays. Compounded formulations permit rapid dosing customization and may align with patients who benefit from stepwise, microdefocused escalation—particularly relevant when genetic predisposition testing suggests variable GLP-1 receptor sensitivity.

Cost Structure, Insurance, and Out-of-Pocket Predictability

Ro charges a consultation fee ($99–$149 per visit) plus the cost of branded medication. Insurance reimbursement for telehealth GLP-1 consultation is variable; most patients pay out-of-pocket for the consultation, though some employer plans or Medicare Advantage plans may cover portions. The total monthly burden typically ranges from $250–$500 depending on medication tier and supply.

Henry Meds employs a similar fee-plus-medication model, with consultation costs ($100–$200) separate from pharmacy charges. Since medications funnel through third-party pharmacies, insurance coverage depends on the individual pharmacy contract and the patient's plan formulary. Compounded GLP-1 protocols, by contrast, often carry transparent per-month pricing ($129-$369/mo) bundled into a single subscription, with no surprise consultation fees or insurance-dependent surprises—simplifying budget planning for patients without GLP-1 coverage.

Safety, Medical Supervision, and Eligibility Screening

Both platforms employ screening questionnaires and consultation assessments to identify contraindications (personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pregnancy, acute kidney injury, severe dehydration). Ro's protocol-driven approach ensures standardized risk assessment; Henry Meds' provider-centric model allows for deeper clinical investigation in complex cases but may vary in thoroughness across practitioners.

Patients with prior GLP-1 intolerance, significant psychiatric comorbidity, or substantial renal/hepatic impairment benefit from individualized evaluation rather than high-volume screening. Henry Meds' independent-provider model may offer this; Ro's efficiency model prioritizes rapid approval for low-risk candidates. Compounded GLP-1 providers who order baseline labs and integrate genetic predisposition insight add an additional safety and personalization layer, particularly for patients with polypharmacy or complex metabolic history.

Personalization, Genetic Insight, and Precision-Medicine Alignment

Neither Ro nor Henry Meds routinely employ genetic testing to predict individual GLP-1 receptor responsiveness or GIPR sensitivity prior to treatment initiation. Both rely on clinical response and tolerance monitoring during therapy. This approach is evidence-based and cost-effective for the majority; however, patients with poor early response, intolerable side effects, or complex metabolic phenotypes may benefit from genetic context around peptide-pathway predispositions.

The Precision Peptide Genetic Test (offered as an add-on within PlexusDx's compounded GLP-1 pathway) examines variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) to reveal individual predispositions in GLP-1 and GLP-1/GIP receptor signaling. This genetic layer does not predict exact medication response but can support more informed conversations between patient and provider about expected tolerability and efficacy trajectories, potentially guiding dose escalation strategy or selection among dual-peptide formulations.

For patients choosing between Ro, Henry Meds, and precision-compounded alternatives, integrating genetic predisposition insight—before or early during treatment—may accelerate identification of personalized dosing pathways, reduce trial-and-error adjustments, and align therapy with individual peptide-pathway biology.

How PlexusDx Supports a More Personalized Approach

PlexusDx partners with licensed 503A compounding pharmacies to formulate semaglutide and tirzepatide at customizable doses, supporting microdose protocols and stepwise titration strategies. Unlike the fixed-schedule approach of mass-market telehealth, compounded formulations enable providers to match dose increments to individual tolerability and response patterns, which may be particularly beneficial for patients with genetic predispositions indicating slower GLP-1 receptor activity or heightened sensitivity to gastrointestinal side effects.

The Precision Peptide Genetic Test adds genetic context to treatment planning without claiming to predict exact medication response. By identifying whether a patient carries variants associated with reduced GLP1R expression or altered GIPR signaling, providers can frame realistic expectations about dose escalation timelines and assist in choosing between single-peptide (semaglutide) and dual-peptide (tirzepatide or GLP-Squared) formulations. This precision-medicine layer complements clinical evaluation and may reduce unnecessary dose failures.

Patients evaluating Ro, Henry Meds, or compounded alternatives should discuss with their provider—or request a provider consultation through PlexusDx—whether genetic insight into peptide-pathway predispositions would enhance confidence in initial dose selection and monitoring strategy. Integrating genetic predisposition context with clinical oversight and compounded-medication flexibility represents a distinct personalization model worth exploring.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the main difference between Ro and Henry Meds?

Ro employs salaried clinicians and uses branded GLP-1 medications through its own pharmacy network, following standardized protocols. Henry Meds connects patients to independent providers whose prescriptions are filled via third-party pharmacies, allowing more variability in clinical evaluation and prescriber specialization.

Do Ro and Henry Meds accept insurance?

Both platforms accept some insurance plans for consultation and medication coverage, but acceptance varies widely by plan and individual state. Most patients pay out-of-pocket for telehealth consultations; medication coverage depends on your formulary and plan details.

Which platform has lower total out-of-pocket costs?

Costs are similar (roughly $250–$500/month combined); Ro charges consultation + medication; Henry Meds uses independent-provider fees plus pharmacy prices. Compounded GLP-1 options often bundle costs into fixed monthly subscriptions ($129-$369/mo), simplifying budgeting for uninsured patients.

Are there safety differences between Ro, Henry Meds, and compounded GLP-1?

All conduct screening and medical oversight; branded medications have extensive post-market data. Compounded formulations are made in licensed 503A pharmacies under USP standards. The key safety advantage of compounded therapy lies in dose customization and integration with genetic predisposition testing for tailored medical supervision.

Can genetic testing help me choose between these platforms?

Genetic testing doesn't predict which platform is 'best,' but the Precision Peptide Genetic Test reveals individual predispositions in GLP-1 receptor pathways. This insight can guide whether microdose, standard-dose, or dual-peptide compounded formulations align with your biology, supporting a deeper conversation with your provider.

Related Reading

• Henry Meds Glp 1
• Henry Meds Tirzepatide
• Henry Meds Cost
• Trimrx Vs Henry Meds Vs Plexusdx

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.